Latest Edge Ai Technology News

dorsaVi has formed a world-class Technical Advisory Board to accelerate its pioneering ‘Intelligence at the Ultra Edge’ strategy, integrating advanced memory and neuromorphic computing into robotics and healthcare devices.

Nanoveu’s subsidiary EMASS has unveiled a breakthrough reference design that integrates inertial sensing with edge AI to enable always-on, ultra-low-power voice interaction in hearable devices. This innovation promises to extend battery life while delivering real-time, hands-free voice control without cloud reliance.

Nanoveu Limited has marked significant progress in its 16nm ECS-DoT edge-AI system-on-chip development, secured a strategic $7.5 million capital raise, and earned top honours at CES 2026, positioning itself for commercial breakthroughs in 2026.

Kincora Copper has begun its inaugural basement drilling at the Wongarbon porphyry project, targeting a major gold-copper system supported by NSW government funding and cutting-edge AI technology.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.

BrainChip Holdings Ltd has launched a fully underwritten $35 million placement alongside a $2 million share purchase plan to fund the commercialization of its Akida 2.0 technology and new TENNs product development. The capital raise underscores the company’s commitment to expanding its footprint in the rapidly growing edge AI market.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

dorsaVi has confirmed its RRAM Reflex Platform achieves biological-grade reflexes with sub-microsecond latency and ultra-low energy use, outperforming leading digital edge AI systems by orders of magnitude.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

BlinkLab has expanded its pivotal FDA autism diagnostic trial by adding the University of Nebraska Medical Center as a second U.S. clinical site, advancing toward broader validation and regulatory clearance.